Details

NameSymbolSector
SANDU PHARMACEUTICALS LTD.SANDUPHQPharmaceuticals
Open
42.44
High
43.54
Low
42.42
Close
43.51
Volume
413
Exchange
bse
Time
15-Jun-2026

Outlook

Score:  

2.75

Rating:  

RISKY

Candlestick Pattern

Candle pattern of Sandu Pharmaceuticals is  
Marubozu
Estimated Stoploss of Sandu Pharmaceuticals is ₹  
42.42
Sandu Pharmaceuticals has a  
Bullishℹ
 pattern. 
Formation of  
Marubozu
 candle pattern indicates Sandu Pharmaceuticals has chances of  
Continuationℹ
 of the current trend. 

Trend

Sandu Pharmaceuticals is in  
Sideways trendℹ
. 
Price of Sandu Pharmaceuticals is  
Upℹ
 by  

7.41

%. 
Target
Buy @ 

31.06

Sell @ 

46.66

Current @ 

43.51

Volume

The trade volumes of Sandu Pharmaceuticals have become  
Deficientℹ
Though the volume trend for Sandu Pharmaceuticals appears  
Bullishℹ
 the participants seem to be  
Weak Buyersℹ
The trade volume of Sandu Pharmaceuticals is  

Down

 by  

94.07

% 

Valuation

The current market price of Sandu Pharmaceuticals is  
Undervaluedℹ

Financials

Balance
With total liablities and shareholder equity worth ₹ 55cr and total assets worth ₹ 55cr, the balance sheet of Sandu Pharmaceuticals is:  
Balancedℹ
. 
Cashflow
Sandu Pharmaceuticals has  
Poorℹ
 cash flow because it is  

₹ 0cr

. It is  
Downℹ
 by  

200

%. 

(*Mar 2025)

0% in operatingℹ
100% in investingℹ
0% in financingℹ
0% in otherℹ
Income
The income of Sandu Pharmaceuticals is  

₹ 17cr

 and  

Loss

 is :  

₹ 0cr

(*Sep 2025)

Sandu Pharmaceuticals Losses increased by:  

0

% and Income is Up by:  

6.25

% 

(*Sep 2025)

The income of Sandu Pharmaceuticals is  

₹ 16cr

 and  

Loss

 is :  

₹ 0cr

(*Jun 2025)

Sandu Pharmaceuticals Losses increased by:  

0

% and Income is Up by:  

14.29

% 

(*Jun 2025)

The income of Sandu Pharmaceuticals is  

₹ 14cr

 and  

Loss

 is :  

₹ 0cr

(*Mar 2025)

Sandu Pharmaceuticals Losses increased by:  

0

% and Income is Down by:  

22.22

% 

(*Mar 2025)

By using this site you agree to the use of cookies to deliver a better site experience.